JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
AstraZeneca plc, a British-Swedish pharmaceutical and biotechnology company, is reportedly withdrawing its COVID-19 vaccine worldwide. The company made the decision months after admitting in court there is a rare side effect.
But then again, according to Channel News Asia, AstraZeneca did not say this was the reason for the pullout of the vaccines. Rather, the company said it was due to “commercial reasons.”
Taking Back the COVID-19 Vaccines Years After Release
AstraZeneca said on Tuesday, May 7, the withdrawal of its vaccines around the world is already underway. It stressed that this is due to a "surplus of available updated vaccines" since the pandemic.
Moreover, the pharmaceutical and biotech firm announced it would also retract the vaccine Vaxzevria's marketing authorizations in Europe. AstraZeneca added that it is no longer producing its COVID-19 vaccine, so supply to the market has also stopped.
“As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company’s spokesman said in a statement. “This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.”
Reported Side Effects of Vaxzevria
AstraZeneca reportedly admitted in court documents that the vaccine has side effects like low platelet counts and blood clots. British newspapers stated that based on legal documents, the company's vaccine may cause TTS, but in very rare cases. World Health Organization (WHO), said this condition called Thrombosis with Thrombocytopenia Syndrome is a serious and life-threatening negative effect.
“It is admitted that the AZ vaccine can, in very rare cases, cause TTS,” AstraZeneca said in court documents in February. “The causal mechanism is not known.”
UK’s The Independent reported that AstraZeneca’s admission came after it was sued in the U.K. The class action lawsuits alleged that the company’s vaccine caused deaths and severe injuries, and claimants are seeking damages up to £100 million for around 50 supposed victims.
Photo by: Mufid Majnun/Unsplash
